Arcturus Therapeutics (ARCT) – Analysts’ Recent Ratings Changes

A number of firms have modified their ratings and price targets on shares of Arcturus Therapeutics (NASDAQ: ARCT) recently:

• 3/10/2025 – Arcturus Therapeutics was given a new $48.00 price target on by analysts at BTIG Research. They now have a “buy” rating on the stock.
• 3/10/2025 – Arcturus Therapeutics had its price target lowered by analysts at Canaccord Genuity Group Inc. from $74.00 to $68.00. They now have a “buy” rating on the stock.
• 3/7/2025 – Arcturus Therapeutics had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
• 3/7/2025 – Arcturus Therapeutics had its price target lowered by analysts at Wells Fargo & Company from $58.00 to $50.00. They now have an “overweight” rating on the stock.
• 3/7/2025 – Arcturus Therapeutics had its price target lowered by analysts at HC Wainwright from $63.00 to $60.00. They now have a “buy” rating on the stock.
• 2/14/2025 – Arcturus Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $63.00 price target on the stock.
• 1/28/2025 – Arcturus Therapeutics is now covered by analysts at BTIG Research. They set a “buy” rating and a $41.00 price target on the stock.

Arcturus Therapeutics Stock Down 2.4 %

ARCT opened at $13.40 on Thursday. The stock has a market cap of $363.41 million, a price-to-earnings ratio of -6.04 and a beta of 2.96. Arcturus Therapeutics Holdings Inc. has a twelve month low of $12.75 and a twelve month high of $45.00. The company’s 50-day moving average price is $16.29 and its two-hundred day moving average price is $18.16.

Arcturus Therapeutics (NASDAQ:ARCT) last released its earnings results on Thursday, March 6th. The biotechnology company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.78). The company had revenue of $22.77 million during the quarter, compared to analysts’ expectations of $44.64 million. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. As a group, sell-side analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current year.

Institutional Trading of Arcturus Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Virtus ETF Advisers LLC raised its position in shares of Arcturus Therapeutics by 38.8% in the fourth quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company’s stock valued at $69,000 after purchasing an additional 1,132 shares during the period. KLP Kapitalforvaltning AS bought a new stake in shares of Arcturus Therapeutics in the fourth quarter valued at approximately $71,000. National Bank of Canada FI raised its position in shares of Arcturus Therapeutics by 639.6% in the fourth quarter. National Bank of Canada FI now owns 5,532 shares of the biotechnology company’s stock valued at $94,000 after purchasing an additional 4,784 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Arcturus Therapeutics by 10.8% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,694 shares of the biotechnology company’s stock valued at $202,000 after purchasing an additional 846 shares during the period. Finally, Kennedy Capital Management LLC raised its position in shares of Arcturus Therapeutics by 22.7% in the fourth quarter. Kennedy Capital Management LLC now owns 10,987 shares of the biotechnology company’s stock valued at $186,000 after purchasing an additional 2,036 shares during the period. Institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.